Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Neuronetics, Inc.

Market Cap 89.07M 0 0 0 0 0 0 0 0 0 0 0 0 P/E ratio 2026 *
-2.76x
P/E ratio 2027 * -3.8x
Enterprise value 89.07M 0 0 0 0 0 0 0 0 0 0 0 0 EV / Sales 2026 *
0.55x
EV / Sales 2027 * 0.5x
Free-Float
67.54%
Yield 2026 *
-
Yield 2027 * -
1 day-0.78%
1 week-23.35%
Current month-16.88%
1 month-22.66%
3 months-7.25%
6 months-1.54%
Current year-7.25%
1 week 1.25
Extreme 1.25
1.49
1 month 1.12
Extreme 1.115
1.74
Current year 0.8
Extreme 0.8
2.48
1 year 0.8
Extreme 0.8
4.85
3 years 0.52
Extreme 0.52
5.92
5 years 0.52
Extreme 0.52
17.92
10 years 0.52
Extreme 0.52
39.39
Manager TitleAgeSince
Chief Executive Officer 63 22/03/2026
Director of Finance/CFO - 04/05/2026
Chief Operating Officer 69 18/06/2025
Director TitleAgeSince
Director/Board Member 67 30/06/2017
Director/Board Member 65 30/09/2019
Chairman 71 26/05/2021
Date Insider Type Main position Quantity % Market Cap.
05-27Free

Director

30,000 0.0454%
05-27Free

Director

30,000 0.0454%
05-27Free

Director

30,000 0.0454%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-23.35%-65.59%-47.11% 89.07M
-0.67%-4.94%+16.85%-8.85% 175B
-0.82%+1.54%-24.86%+34.68% 148B
-0.42%+2.03%-6.37%-22.04% 130B
+0.31%+1.50%-52.30%-4.64% 72.39B
-0.13%-2.62%+10.75%+2.25% 49.43B
+0.68%+1.44%-25.92%-34.03% 44.28B
-2.03%-2.42%+14.59%+15.69% 37.48B
-0.55%-3.92%+3.47%+45.36% 35.67B
0.00%+3.16%-9.70%-16.82% 29.42B
Average -0.51%-2.64%-13.91%-3.55% 72.14B
Weighted average by Cap. -0.55%-0.59%-7.76%+0.98%

Financials

2026 *2027 *
Net sales 161M 0 0 0 0 0 0 0 0 0 0 0 0 178M 0 0 0 0 0 0 0 0 0 0 0 0
Net income -32.87M -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -25.74M -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Net Debt - -
Logo Neuronetics, Inc.
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Employees
658
Date Price Change Volume
08/06/26 1.280 $ -0.78% 1,229,666
05/06/26 1.290 $ -11.64% 2,009,885
04/06/26 1.460 $ +5.04% 1,048,899
03/06/26 1.390 $ -10.90% 1,833,272
02/06/26 1.560 $ -6.59% 1,117,891
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.280USD
Average target price
4.333USD
Spread / Average Target
+238.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STIM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW